Objective: S100B is viewed as the most promising biomarker for brain damage. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. This study aims to examine the clinical usefulness of daily serum S100B measurements in this setting.
View Article and Find Full Text PDFActa Neurol Scand
April 2006
Background: This study investigates current management practice of children with MHI in Swedish hospitals to define present need for management guidelines for children.
Methods: A cross-sectional mail survey including 51 hospitals treating children with MHI outlines management routines concerning clinical and radiological examinations, in-hospital observation, discharge criteria and follow-up.
Results: Twenty-seven per cent of the hospitals have established written criteria for referral and management of children with MHI.
Protein S100B is today the most promising biomarker for cerebral injury. A welcomed area for the use of such a marker is in the early stages of head trauma and diagnosis of brain injury, in particular epidural haematomas. We report five consecutive cases of epidural haematoma where serum samples for S100B were drawn at admission.
View Article and Find Full Text PDF